Letters Bevacizumab and ranibizumab

A matter of public interest

BMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c3721 (Published 13 July 2010) Cite this as: BMJ 2010;341:c3721
  1. Silvio Garattini, director1,
  2. Vittorio Bertele’, head, drug regulatory policies laboratory1
  1. 1Mario Negri Institute for Pharmacological Research, via Giuseppe La Masa 19, 20156 Milan, Italy
  1. silvio.garattini{at}marionegri.it

    Bevacizumab is better than no treatment, photodynamic treatment, or six weekly intravitreal pegaptanib sodium in neovascular age related macular degeneration (AMD).1 Its long term safety and whether it is as effective as ranibizumab are unknown,2 but available data should be sufficient for the European Medicine Agency (EMA) to …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial